We conducted a phase I trial to determine the dose and schedule of paclitaxel, when given together with filgrastim, which would optimally promote mobilization of stem cells with tolerable toxicity. Dose escalation began at 275 mg/m 2 3 h infusion. Dose-limiting neuropathy was observed at the 300 mg/m 2 dose level. A second dose escalation was conducted utilizing 24 h infusion schedules, beginning at 225 mg/m 2 . Dose escalation was continued by 25 mg/m 2 increments to 300 mg/m 2 , at which dose neuropathy was again dose-limiting. The recommended dose and schedule of paclitaxel for the purpose of mobilization of stem cells, when given together with filgrastim, are 275 mg/m 2 as a 24 h infusion. The median stem cell yield after this dose of paclitaxel was 6.6 ؋ 10 6 CD34 ؉ cells/kg/apheresis (range 3.6 ؋ 10 6 -7.7 ؋ 10 6 ). Keywords: breast neoplasm; mobilization; stem cells; paclitaxel Peripheral blood progenitor cells are now preferred to bone marrow for hematopoietic reconstitution after high-dose chemotherapy because they are associated with shorter periods of cytopenia and fewer acute complications. Rapid hematopoietic recovery following stem cell infusion renders multicycle high-dose chemotherapy feasible, which has led to improvements in complete response rates in the treatment of metastatic breast cancer.
Peripheral blood progenitor cells are now preferred to bone marrow for hematopoietic reconstitution after high-dose chemotherapy because they are associated with shorter periods of cytopenia and fewer acute complications. Rapid hematopoietic recovery following stem cell infusion renders multicycle high-dose chemotherapy feasible, which has led to improvements in complete response rates in the treatment of metastatic breast cancer. 1 The risk of reintroducing malignant cells may be reduced with the use of peripheral blood stem cells, compared with bone marrow. 2 The optimal means of mobilizing peripheral blood stem cells is not known. Adequate numbers of stem cells, estimated by CD34 ϩ cell determination, can be obtained by apheresis after administration of colony-stimulating factors or during rebound leukocytosis after moderately or severely myelosuppressive chemotherapy. CD34
ϩ cells collected after the use of filgrastim are significantly less likely to undergo apoptosis than are CD34 ϩ cells in the peripheral blood in the unstimulated state. 3 Non-randomized comparisons suggest that hematopoietic recovery will be shortened after infusion of peripheral blood progenitor cells harvested during filgrastim-supported recovery from chemotherapy. 4, 5 There is an inverse relationship between yield and prior treatment with radiotherapy and chemotherapy, and this is the most important predictive factor for yield. Among patients with relapsed breast cancer, prior adjuvant therapy and radiotherapy may impair mobilization. In addition, the recent trend towards greater use of double or multicycle high-dose therapy, and use of purging systems which may reduce cell number, have created a need for higher stem cell yields. Use of chemotherapy to aid in the mobilization of stem cells had been reported by Brugger et al 6 to mobilize epithelial cells in a time-dependent manner, but subsequent investigators have found no significant difference in contamination of progenitor cells mobilized by filgrastim alone compared with an historical group mobilized with high-dose cyclophosphamide followed by GM-CSF. 7 Paclitaxel contributes to mobilization in combination with high-dose cyclophosphamide, epirubicin, or cyclophosphamide and etoposide. [8] [9] [10] [11] [12] [13] Paclitaxel as a single agent has potential advantages over the high-dose and combination mobilizing regimens in current use: it rapidly induces a leukocyte nadir which is of brief duration, does not cause severe thrombocytopenia, is active at standard doses against the malignancies for which high-dose chemotherapy is most often considered, and has less toxicity than high-dose and combination regimens. It can be used safely in the setting of doxorubicin-induced cardiomyopathy.
14 We conducted the current phase I study to determine the optimum dose and schedule of paclitaxel alone to promote a high circulating CD34
ϩ cell count and permit stem cell harvesting.
Materials and methods

Patient selection
Patients were eligible if they were already receiving paclitaxel chemotherapy and were candidates to receive highdose chemotherapy with peripheral blood stem cell rescue.
Patients with advanced breast, ovarian and testicular cancer were eligible. Other requirements were an ECOG performance status of 0 or 1, age у18 years, absolute neutrophil count of 1500/l, platelet count of 100 000/l, and informed, written consent. The consent form was approved by the Yale University Human Investigation Committee, the Danbury Hospital Institutional Review Board, and the UCSD Institutional Review Board. Patients were excluded if they had demonstrated life-threatening hypersensitivity to previous doses of paclitaxel, had received prior mitomycin, cisplatin or nitrosourea chemotherapy, had brain metastases or had received radiotherapy to the brain, or had other serious active medical or psychiatric disease. Patients were also excluded if they had received more than 500 mg/m 2 of an anthracycline, had an ejection fraction of Ͻ40%, or had wall motion abnormalities. These exclusions were made because we were not routinely offering stem cell transplantion to patients with cardiomyopathy, and not because cardiomyopathy is an absolute contraindication to the use of paclitaxel at these doses. Patients could not be pregnant, be within the first 2 weeks after major surgery, or have a history of prior malignancy, except for cervical carcinoma in situ or non-melanoma skin cancer.
Treatment plan
Pre-treatment evaluation consisted of history and physical examination, chest radiograph, electrocardiogram, equilibrium radionuclide angiography, MR of the brain, complete blood count (CBC), serum chemistries, bone marrow aspiration and biopsy, urinalysis and creatinine clearance.
A double-lumen central vascular access device suitable for leukapheresis was inserted and the patients were instructed in catheter care. Patients received dexamethasone 20 mg p.o. 14 and 7 h prior to paclitaxel. Paclitaxel was administered intravenously with cimetidine and diphenhydramine premedication. For patients on the first two dose levels, this was as a 3 h infusion in the outpatient department. For patients on the subsequent dose levels, this was as a 24 h infusion via an ambulatory infusion device.
The initial dose was 275 mg/m 2 , based on actual body weight. For patients more than 40% above ideal body weight, the average of the ideal and actual weight was used to calculate body surface area. Three patients were treated at each dose level. If dose-limiting toxicity was observed in any one patient, enrollment on that dose level continued to six patients or until two patients had dose-limiting toxicity, whichever occurred first. If dose-limiting toxicity with the 3 h infusion was neurotoxicity, the treatment plan called for a second dose escalation with a 24 h infusion schedule. Dose-limiting toxicity was defined as grade IV infection, grade IV hematologic toxicity persisting beyond 14 days, grade III non-hematologic toxicity, or lifethreatening hypersensitivity reaction. Additional patients were also enrolled on a given dose level if any patient failed to mobilize. Mobilization failure was defined as failure to achieve a CD34 ϩ cell collection of 2.5 ϫ 10 6 CD34 ϩ cells/kg within six apheresis procedures; or as any daily yield below 0.4 ϫ 10 6 CD34 ϩ cells/kg without an increase in the peripheral CD34 ϩ cell count on the subsequent day. Daily filgrastim was begun on day 3 and continued to the end of leukapheresis. The dose was 300 or 480 g, whichever was closer to 5 g/kg, and was administered subcutaneously. A CBC was performed on alternate days until the nadir and then daily to the conclusion of leukapheresis. Prophylactic ciprofloxacin 500 mg p.o. was administered twice daily when the neutrophil count was Ͻ1 ϫ 10 9 /l. If neutropenic fever developed during ciprofloxacin prophylaxis, patients were hospitalized for intravenous broad-spectrum antibiotics.
Leukapheresis was commenced upon recovery of the white blood cell count from its nadir, or upon CD34 ϩ count greater than 20 cells/nl. Absence of fever and recent negative blood culture were also required before leukapheresis for patients who had required treatment for neutropenic fever. The mononuclear cell collection procedure was performed with either a CS-3000 plus blood cell separator (Baxter, Fenwall Division, Round Lake, IL, USA) or a COBE Spectra (COBE BCT, Lakewood, CO, USA). The procedures were performed using an appropriate central venous access catheter. Collections using the CS-3000 plus were performed according to the manufacturer's protocol (special procedure 1-4), with the flow rate adjusted based on hematocrit. Cells were collected at 60-80 ml/min for a total of 12 l blood processed. For collection on the COBE spectra, the 'MNC' procedure was selected. All patients after patient No. 3 received prophylactic calcium gluconate infusion intravenously.
Of the 24 patients enrolled, 21 underwent high-dose chemotherapy with stem cell reinfusion. Two patients did not proceed with high-dose chemotherapy because of progression of disease that occurred between stem cell collection and the scheduled start of high-dose chemotherapy. One did not because of inadequate mobilization despite repeated attempts. One patient received a single cycle of combination cyclophosphamide, thiotepa and carboplatin with stem cell support; a second received a single cycle of high-dose melphalan; a third tandem transplant consisting of high-dose carboplatin, mitoxantrone and cyclophosphamide in the first cycles and carboplatin, etoposide and thiotepa in the second; and the remainder of the patients received sequential single-agent high-dose therapy with melphalan 140 mg/m 2 for the first cycle and thiotepa 700 or 900 mg/m 2 for the second cycle. 15 Each cycle of highdose chemotherapy was rescued with at least 2.5 ϫ 10 6
CD34
ϩ cells/kg. The protocol did not dictate whether paclitaxel-or cyclophosphamide-mobilized cells were to be used for reconstitution following a given cycle.
Results
Patient characteristics
Twenty-four patients were enrolled. Patient characteristics are presented in Table 1 . The median age was 44.5 years (range 32-59). All patients were female. Twenty-two had stage IV breast cancer and two had stage IIIB breast cancer. The median ECOG performance status was 0 (range 0-1). All patients had received at least one chemotherapy regimen prior to paclitaxel. In 23 patients, a prior chemotherapy regimen contained doxorubicin. Fourteen patients had received prior radiotherapy. Ten of the patients had received prior hormonal therapy. 
Dose levels
The first four patients were treated with paclitaxel 275 mg/m 2 administered as a 3 h infusion. The subsequent dose level was 300 mg/m 2 over 3 h. The dose-limiting toxicity observed at this dose level was neurotoxicity. Neuropathy has previously been reported to be dose-limiting for paclitaxel when short infusion times are used. 16 A second dose escalation was performed with a 24 h infusion schedule, beginning at 225 mg/m 2 , escalating by 25 mg/m 2 increments and continuing until dose-limiting toxicity was again seen in уtwo of six patients. Dose levels are presented in Table 2 .
Toxicities
No dose-limiting toxicity was seen at dose level I. One patient had non-neutropenic fever and a late rash, possibly consistent with hypersensitivity to paclitaxel. Grade 3 neurotoxicity was observed in two of three patients treated at dose level II. The third patient was unable to receive the full dose because she developed scotomata during the infusion. The infusion was stopped, and the total dose she received was 230 mg/m 2 . Two patients had culturedocumented infections, although the absolute neutrophil count did not fall below 1 ϫ 10 6 /l in any patient treated at this dose level.
No dose-limiting toxicity was seen in any patient on dose level III. One patient had grade 4 neutropenia. The mean duration of grade 4 neutropenia at dose level IV was 1.6 days (range 0-3 days). One of seven patients had neutropenic fever and one had grade 2 non-neutropenic fever. Two of three patients at dose level V had grade 2 neuropathy and one had grade 2 bone pain. The median duration of grade 4 neutropenia was 1 day (range 0-2). Two of four patients who were treated on dose level VI had grade 3 neuropathy. Three patients had fever; this was associated with neutropenia in two cases. The median duration of grade 4 neutropenia was 2 days (range [1] [2] [3] . No patient at any dose level required a platelet transfusion.
Stem cell yield
The time to apheresis, total stem cell yield and number of apheresis procedures for each patient are shown in Table 3 . The mean time to pheresis for each dose level was 9 days or less. An inadequate collection was achieved from one of four patients on dose level I because of symptoms of hypocalcemia during the pheresis procedure; and in one of three patients on dose level II because of line sepsis with persistent bacteremia during the period of CD34 ϩ cell mobilization. The mean stem cell yield for the 3 h infusion dose levels was 3.9 ϫ 10 6 CD34 ϩ cells/kg. The mean yield on dose level III was 6.67 ϫ 10 6 CD34 ϩ cells/kg (range 2.55-7.90). One of seven patients on dose level IV had an inadequate collection. Another was not collected because of infection. The mean yield for the six patients on this dose level who had at least one apheresis procedure was 4.2 ϫ 10 6 CD34 ϩ cells/kg. All patients on dose level V had adequate collections and the mean yield was 6.0 ϫ 10 6
CD34
ϩ cells/kg. One of four patients on dose level VI did not mobilize. This patient had received high-dose cyclophosphamide as adjuvant therapy. She also failed to mobilize with a second chemotherapy/filgrastim regimen. The mean yield at dose level VI was 4.3 ϫ 10 6 CD34 ϩ cells/kg. Omitting the patient who failed to mobilize, the mean yield at this dose level was 5.8 ϫ 10 6 CD34 ϩ cells/kg. Eighteen of the patients subsequently underwent mobilization with cyclophosphamide 5 g/m 2 and filgrastim. The median time to pheresis after cyclophosphamide was 14 days. The mean yield per apheresis procedure was 5.0 ϫ 10 6 CD34 ϩ cells/kg.
Hematopoietic recovery following stem cell infusion
Paclitaxel-mobilized cells supported rapid hematopoietic reconstitution. Three patients underwent re-infusion of both paclitaxel-and cyclophosphamide-mobilized cells, and 16 patients received paclitaxel-mobilized cells only. The median time to an absolute neutrophil count above 0.5 ϫ 10 6 /1 for all patients was 9 days. 
Discussion
Single-agent paclitaxel given with filgrastim support is a safe, effective and reliable way to mobilize stem cells from patients who have received prior chemotherapy and radiotherapy. We collected at least 2.5 ϫ 10 6 CD34 ϩ cells/kg from 20 of 24 breast cancer patients. The hematopoietic recovery we observed after infusion of stem cells collected in this manner is comparable to that reported by investigators who used high-dose or combination chemotherapy regimens supported by filgrastim. 5, 13 The toxicity of this means of stem cell collection is moderate, and reduced in comparison with historical reports of paclitaxel in combination with high-dose cyclophosphamide. 13 The doselimiting toxicities we observed were those that have previously been observed with these doses and schedules of paclitaxel. 17, 18 There was no evidence in our study of cardiotoxicity of paclitaxel at doses of 275 or 300 mg/m 2 as a 3 h infusion or 225-300 mg/m 2 as a 24 h infusion. As high-dose cyclophosphamide is contraindicated in patients with cardiomyopathy, and as doxorubicin-induced cardiomyopathy is a not infrequent event in patients with breast cancer, this may provide a means for collecting stem cells from patients with doxorubicin-induced cardiac injury.
The short time from chemotherapy administration to stem cell collection may minimize contamination of the stem cell product with malignant cells, as suggested by Brugger et al. 6 Further studies are underway in our laboratory to compare contamination of paclitaxel-with cyclophosphamide-mobilized cells.
The recommended phase II dose for the purpose of mobilizing stem cells is 275 mg/m 2 given as a 24 h infusion. No grade 3 or 4 neurotoxicity was seen at this dose level, no neutropenic fever was seen, and all patients had successful stem cell collections with a median yield per procedure of 6.0 ϫ 10 6 CD34 ϩ cells/kg. Neurotoxicity was dose-limiting at the higher dose level. Although lower dose levels also resulted in successful stem cell collections with less toxicity, the highest feasible dose is recommended because it is likely that there is a dose-response relationship for paclitaxel, and if this is so, the higher dose will make a greater contribution toward cytoreduction. 19 The failure of mobilization in one patient on dose level IV may have been idiosyncratic, related to extensive adjuvant chemotherapy and bone marrow metastases. A second patient at this dose level was the only patient whose CD34 ϩ count was determined in another laboratory. Omitting these two patients, the mean yield at this dose level was 6.02 ϫ 10 6 CD34 ϩ cells/kg, which is comparable with the yields obtained at the other dose levels which used a 24 h infusion schedule. This was the dose and schedule we used in the pilot phase of this project, where mobilization failure was not seen. 20 Further studies should examine the relationship of the means of stimulating stem cell mobilization and the timing of collection with the likelihood that the collection of stem cells will be contaminated with tumor cells; and should assess the impact of such contamination on patient outcome.
